Sign In to Follow Application
View All Documents & Correspondence

Novel N Heterocyclic Lipophilic Chalcones

Abstract: Disclosed is the synthesis, analysis, assessment of biological activities and in silico studies of series of di-heterocyclic chalcones synthesized using N-alkylated heterocyclic aldehyde in combination with 3-acetyl pyridine and heterocyclic aldehydes in combination with alkyl halides, under room temperature and nitrogen atmosphere. The synthesized chalcones were purified and assessed for their anti-cancer properties against A549 (lung cancer), AGS (gastric cancer), BT474, MDA-MB-231, MCF7 (breast cancer), and HaCaT cell lines. Chalcones bearing indole and pyridine with hexyl and octyl chains on indole nitrogen were found to have activity against the A549 cell line with IC50 values of 47.5 and 54.5 µM. The pyrrole-pyridine demonstrated good activity against MCF7 cells. Some of the synthesized chalcones screened against MDA-MB-231 cells demonstrated good inhibition percentage of more than 55%. Synthesized chalcones also showed least cytotoxicity against cell lines. Molecular docking studies of the synthesized

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
23 May 2025
Publication Number
23/2025
Publication Type
INA
Invention Field
CHEMICAL
Status
Email
Parent Application

Applicants

AMRITA VISHWA VIDYAPEETHAM
Coimbatore Campus Coimbatore- 641 112, Tamil Nadu, India

Inventors

1. RAMANI, Prasanna
B7A Staff Quarters Amrita University Ettimadai PO Coimbatore, Tamil Nadu 641112 India
2. RAJENDRAN, Gayathri
Kanichadath, Palath, Kakkodi Kozhikode, Kerala 673611

Specification

Description:FIELD OF INVENTION:
The present invention relates to the synthesis of two series of di-heterocyclic chalcones using heterocyclic aldehyde and 3-acetyl pyridine. More particularly, the present invention discloses the synthesis, analysis, assessment of biological activities and in silico studies of the di-heterocyclic chalcones.

BACKGROUND OF INVENTION:
Cancer is one of the deadliest metastatic diseases, which itself is a combination of multiple diseases. The number of cancer cases diagnosed in the United States in 2024 are almost a little over 2 million. Most cases are reported in prostate, breast, lung, and colon cancer among which breast cancer is the leading cancer among women. There are many FDA-approved drugs available in the market and heterocyclic units are major constituents of most of them. Both synthetic and naturally occurring chalcones show enhanced activity against lung, breast, and colon cancer, and also against neurodegenerative disorders such as Alzheimer’s and Parkinson’s with potent MAO-A a , Claims:WE CLAIM:
1. Di heterocyclic chalcone compounds comprising:
- indole and pyridine-based di heterocyclic chalcone, as represented by Formula A;

Formula A
- pyrrole and pyridine-based di heterocyclic chalcone, as represented by Formula B;

Formula B
wherein, chalcone of formula A comprises of N-alkylated indole-3-carboxaldehyde and 3-acetyl pyridine and chalcone of formula B comprises of N-alkylated pyrrole-2-carbaldehyde and 3-acetyl pyridine,
such that the synthesized chalcones are potent inhibitory agents for major types of cancer.
2. The synthesized chalcone compounds as claimed in claim 1, wherein the solvent employed is ethanol or methanol or a combination of methanol and ethanol.
3. The synthesized chalcone compounds as claimed in claim 1, wherein the said chalcones were synthesized at room temperature under nitrogen or argon atmosphere.
4. The synthesized chalcone compounds as claimed in claim 1, wherein the chalcones were synthesized using NaOH or KOH or pyridine or piperidine as a base.
5. The s

Documents

Application Documents

# Name Date
1 202541049602-STATEMENT OF UNDERTAKING (FORM 3) [23-05-2025(online)].pdf 2025-05-23
2 202541049602-FORM-9 [23-05-2025(online)].pdf 2025-05-23
3 202541049602-FORM FOR SMALL ENTITY(FORM-28) [23-05-2025(online)].pdf 2025-05-23
4 202541049602-FORM 18 [23-05-2025(online)].pdf 2025-05-23
5 202541049602-FORM 1 [23-05-2025(online)].pdf 2025-05-23
6 202541049602-FIGURE OF ABSTRACT [23-05-2025(online)].pdf 2025-05-23
7 202541049602-EVIDENCE FOR REGISTRATION UNDER SSI(FORM-28) [23-05-2025(online)].pdf 2025-05-23
8 202541049602-EVIDENCE FOR REGISTRATION UNDER SSI [23-05-2025(online)].pdf 2025-05-23
9 202541049602-EDUCATIONAL INSTITUTION(S) [23-05-2025(online)].pdf 2025-05-23
10 202541049602-DRAWINGS [23-05-2025(online)].pdf 2025-05-23
11 202541049602-DECLARATION OF INVENTORSHIP (FORM 5) [23-05-2025(online)].pdf 2025-05-23
12 202541049602-COMPLETE SPECIFICATION [23-05-2025(online)].pdf 2025-05-23
13 202541049602-Proof of Right [20-08-2025(online)].pdf 2025-08-20
14 202541049602-FORM-26 [20-08-2025(online)].pdf 2025-08-20
15 202541049602-Request Letter-Correspondence [08-10-2025(online)].pdf 2025-10-08
16 202541049602-Power of Attorney [08-10-2025(online)].pdf 2025-10-08
17 202541049602-FORM28 [08-10-2025(online)].pdf 2025-10-08
18 202541049602-Form 1 (Submitted on date of filing) [08-10-2025(online)].pdf 2025-10-08
19 202541049602-Covering Letter [08-10-2025(online)].pdf 2025-10-08
20 202541049602-CERTIFIED COPIES TRANSMISSION TO IB [08-10-2025(online)].pdf 2025-10-08